Abstract: The present invention relates to novel liquid pharmaceutical compositions comprising proteins, preferably antibodies as defined herein together with one or more surfactants selected from TPGS, PVA, T1107, Px338, Px407, TMN-6, 15-S-15, Chol-PEG, and SL.

Abstract: Cosmetic oil-in-water emulsion (O/W emulsion) containing a) hydroxypropyl starch phosphate and b) one or more perfumes selected from the group of the compounds of the tertiary alcohols, acyclic terpinolenes, and benzopyrones, wherein the preparation is free of carbomers and polyacrylates.

Abstract: Cosmetic product of a) a cosmetic preparation containing hydroxypropyl starch phosphate (INCI: Hydroxypropyl Starch Phosphate) and b) a packaging with a dispensing opening in the form of a hole from which the cosmetic preparation can be dispensed in the form of a flow.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: This invention relates to a pharmaceutical formulation of a bispecific anti-VEGF/ANG2 antibody, and a process for the preparation and uses of the formulation.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: The invention relates to a cosmetic spray consisting of a) an oil-in-water emulsion (O/W emulsion) containing poly glyceryl-10 stearate and b) a spray applicator system.

Abstract: The invention relates to a cosmetic foam made from a) an O/W emulsion containing glycerine and b) mono- and/or polyvalent alcohols with a carbon chain length of less than 12 C-atoms and c) a gas or gas mixture of propane, n-butane and/or isobutane, foaming the emulsion, which emulsion is fre of polyethylene glycol derivatives (PEG derivatives).

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: The invention relates to a cosmetic foam of a) an emulsion containing a combination of sodium cetearyl sulfate and glyceryl monostearate SE and b) a gas or gas mixture of propane, n-butane and/or isobutane, foaming the emulsion, the emulsion being free of polyethylene glycol derivatives (PEG derivatives).

Abstract: Anti-CD40 antibodies are formulated as lyophilizate or liquid formulation. The lyophilizates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilizate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilizate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: The invention relates to a cosmetic spray which consists of a) an oil-in-water emulsion (O/W emulsion) that contains i) polyglyceryl-3 methylglucose distearate and ii) acrylate/C10-30 alkyl acrylate crosspolymer, and b) a spray applicator system.

Abstract: The invention relates to a cosmetic spray consisting of a) an oil-in-water emulsion (O/W emulsion) containing poly glyceryl-10 stearate and b) a spray applicator system.

Abstract: The invention relates to a cosmetic spray consisting of a) an oil-in-water emulsion (0/W emulsion) containing sodium stearoyl glutamate and b) a spray applicator system.

Abstract: An amphoteric liposome composed of a mixture of lipids, said mixture comprising a cationic amphiphile, an anionic amphiphile and optionally one or more neutral amphiphiles, at least one of said cationic and anionic amphiphiles being chargeable and the respective amounts of said cationic and anionic amphiphiles being selected such there is a stoichiometric excess of positively charged cationic amphiphile at a first lower pH, a stoichiometric excess of negatively charged anionic amphiphile at a second higher pH and said mixture has an isoelectric point intermediate said first and second pHs; characterised in that said positively charged cationic and negatively charged anionic amphiphiles are adapted to form a lipid salt with one another at said isoelectric point. Also disclosed are methods of predicting the fusogenicity of an amphoteric liposome at a given pH, formulating an amphoteric liposome and loading an amphoteric liposome with a cargo moiety.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: The present invention is directed to stable protein formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing therapeutic proteins in aqueous solution.